Efficiency of amniotic membrane transplantation in the management of limbal stem cell deficiency by Procopciuc, Vitalie et al.
100 Arta
Medica
.Nr. 3 (76), 2020Congresul Consacrat Aniversării a 75-a de la Fondarea USMF ”Nicolae Testemițanu”
EFFICIENCY OF AMNIOTIC MEMBRANE TRANSPLANTATION IN 
THE MANAGEMENT OF LIMBAL STEM CELL DEFICIENCY
Vitalie Procopciuc1,4, PhD student, Viorica Mihaluța2, PhD student, Olga Ignatov3,4, PhD student, Valeriu Cușnir1, 
PhD in Medical Sciences, professor, Viorel Nacu4, PhD in Medical Sciences,  professor
1 State University of Medicine and Pharmacy “Nicolae Testemiţanu”, Department of Ophthalmology-Optometry, Chișinău, 
Republic of Moldova
2 State University of Medicine and Pharmacy “Nicolae Testemiţanu”, Department of Surgery no. 2, Chișinău, Republic of 
Moldova
3 State University of Medicine and Pharmacy “Nicolae Testemiţanu”, Department of Medical Rehabilitation, Physical 
Medicine and Manual Therapy, Chișinău, Republic of Moldova
4 Laboratory of Tissue Engineering and Cell Cultures, Chișinău, Republic of Moldova
Abstract
Objectives. This paper aims to examine the efficacy, safety, and long term outcomes of amniotic membrane transplantation for corneal surface 
reconstruction, in cases of limbal stem cell deficiency.
Material and methods. A systematic literature search was performed on PubMed, for papers published up to February 2020, using the following combined 
search terms: "limbal stem cell deficiency", "amniotic membrane", "limbal transplant". Only clinical trials with human subjects were selected for analysis. 
We collected the data on amniotic membrane properties and mechanisms of action, processing, preservation and transplantation techniques, and clinical 
outcomes of different treatment methods.
Results. The surgical approach for treating limbal stem cell deficiency depends on the extent of the disease. Isolated amniotic membrane transplantation 
appears to have a limited beneficial effect on limbal stem cells, whereas amniotic membrane transplantation, combined with certain types of limbal 
stem cell transplantation, provides long-term biological and mechanical support for the donor tissue explants. Combined with simple limbal epithelial 
transplantation, the amniotic membrane has shown excellent results in the surgical management of limbal stem cell deficiency. 
Conclusions. Preliminary results of amniotic membrane use in limbal transplantation show quite satisfactory data, but the lack of high-level randomized 
controlled studies makes it difficult to assess the comparative efficacy of amniotic membrane transplantation in limbal stem cell deficiency surgical 
management.
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Introduction
Limbal stem cells (LSC) have the function of regenerating 
corneal epithelial cells, as well as maintaining the integrity of 
the corneal epithelium [1]. Various ocular pathologies can affect 
the limbal region, causing LSC dysfunction. Limbal stem cell 
deficiency (LSCD) is a condition characterized by a number 
of pathological signs: delayed or incomplete regeneration of 
epithelial lesions, recurrent epithelial erosions, scarring and 
stromal opacity, prolonged corneal edema after cataract surgery, 
rejection of the corneal graft, etc. [2] Among the causes of LSCD 
are pathologies such as: chemical and thermal burns, severe 
microbial infections, chronic cicatricial inflammation (Stevens-
Johnson syndrome and bullous pemphigoid), incorrect wearing 
of contact lenses, trauma, etc. [3]
LSCD treatment is not an easy task, and attempts to restore 
the integrity and functionality of LSC are often in vain. It 
should be noted that corneal transplantation cannot treat LSCD 
and usually fails after surgery. Therefore, LSCD management 
requires a complex approach and, most of the time, the 
combination of several treatment methods. Medical therapy 
has a limited success rate and is only appropriate in mild cases 
[4]. All cases of moderate to severe LSCD require surgical 
management. The main directions of LSCD surgical treatment 
are: direct limbal tissue transplantation and ex vivo/in vivo 
expanded LSC transplantation [5]. The amniotic membrane 
(AM), used alone or as a substrate for LSC, can be incorporated 
into LSC transplantation in almost all surgical approaches. This 
review aims to investigate the role of AM and its effectiveness in 
the surgical management of LSCD.
Material and methods
In this paper, we reviewed the literature in order to analyze 
current data on applications of amniotic membrane in surgical 
management of limbal stem cell deficiency and summarized the 
results of different surgical approaches. A systematic literature 
search was performed on PubMed for papers published 
up to February 2020, using the following combined search 
terms: "limbal stem cell deficiency", "amniotic membrane", 
"limbal transplant". Only clinical trials with human subjects 
were selected for analysis. We collected the data on amniotic 
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membrane properties and mechanisms of action, processing, 
preservation and transplantation techniques, and clinical 
outcomes of different treatment methods.
Results
A. Structure, properties and mechanisms of action of the 
amniotic membrane
AM is a biological material of the human placenta, 
constituting the inner wall of fetal membranes [6]. It has a fetal 
part - the chorion, and a maternal component - the decidua. 
Histologically, it consists of a monolayered epithelium, rich in 
collagen basement membrane, and stroma. Amniotic epithelial 
cells have qualities that make them a very good source of stem 
cells. Thus, studies have shown that these cells have "stem-like" 
characteristics, as they express surface cell markers associated 
with embryonic stem cells (such as SSEA 3 and SSEA 4), TRA 
1-60 and TRA 1-81. It should also be noted that these cells 
express transcription factors specific to pluripotent stem cells, 
such as Oct-4 ("octamer binding transcription factor"), which 
suggests the pluripotent ability to differentiate [7].
The amniotic membrane transplantation (AMT) can be used 
either as a graft, to replace damaged tissue on the eye surface, 
or as a tissue patch to prevent the spread of inflammation. The 
mechanisms of action are: anti-inflammatory, antiangiogenic, 
facilitator of epithelialization. Also, through the biological 
similarity between the conjunctiva and the amniotic basement 
membrane, the latter can be a matrix for the development of 
epithelial cells, supporting their differentiation and nutrition and 
prolonging their lifespan. The AM functions as a substrate for 
stem cell expansion, with implications in the treatment of LSCD 
of various etiologies and in facilitating the epithelialization of 
severe corneal ulcers with epithelial and stromal destruction [8].
Restoring ocular homeostasis after a severe disease 
is a challenge, due to its complexity, which requires both 
reconstructive surgery and the modulation of cellular 
mechanisms of inflammation, scarring and tissue regeneration 
in vitro.
AM has many beneficial properties:
• anti-inflammatory: AM produces natural inhibitors of me-
talloproteinases and suppresses the pro-inflammatory cytokines 
IL1-alpha and IL1-beta [9]; AM, also, induces apoptosis of 
inflammatory cells in chemical burns of the ocular surface [10].
• antimicrobial: AM produces beta defensins and proteinase 
inhibitors, adhering tightly to the damaged surface and 
constituting a barrier against the external environment [11];
• antifibrotic and antiadhesive: AM secretes the tissue inhi-
bitor of metalloproteinase, which inhibits protease activity, with 
the reduction of tissue fibrosis; also, by inhibiting TGF beta, 
the inactivation of fibroblasts is obtained, which prevents the 
formation of adhesions between the damaged tissue surfaces 
[12];
• immunological inertia and low level of antigenicity: these 
translate into very low expression of histocompatibility antigens 
HLA, B, CDR, beta-2-microglobulin and unique surface and 
biochemical properties of placental membranes, which do not 
express the MHC II class of histocompatibility antigens [13];
• analgesic: rapid pain reduction, by effectively covering the 
nerve endings [14];
• antiangiogenic: AM epithelial cells express antiangiogenic 
molecules, such as thrombospondin-1 and endostatin; metallo-
proteinase inhibitors have also been isolated in amniotic 
epithelial cells: type 1, 2, 3, 4; at the level of the amniotic 
basement membrane was identified the pigment epithelial 
derived factor (PEDF), with strong anti-angiogenic properties; 
recent studies have shown that the antiangiogenic effect of the 
AM may be influenced by the presence of inflammation and the 
type of pathology [9, 15];
• promoter of cell differentiation and deionization, through 
the content of type IV, V and VII collagen [16];
• favoring epithelialization, through several mechanisms: 
the amniotic basement membrane represents the support for the 
growth of epithelial cells and maintaining their functionality; at 
the level of AM, the migration and differentiation of epithelial 
cells is facilitated; collagen-rich amniotic basement membrane 
is a very good substrate for re-epithelialization; at the level of 
AM are expressed several growth factors: KGF (keratinocyte 
growth factor – present in the epithelialization phase of wound 
healing, when keratinocytes cover the wound); bFGF (basic 
fibroblast growth factor – involved in angiogenesis, wound 
healing, embryo development); HGF (hepatocyte growth factor 
– that regulates cell growth, motility and morphogenesis); 
TGF-beta (transforming growth factor beta – that controls cell 
proliferation and differentiation) [16, 17].
B. Limbal stem cells - anatomy, physiology and pathology
The ocular surface is an anatomical assembly, consisting of 
three contiguous structures: conjunctiva, limbus and cornea. 
The limbus is the anatomical barrier between the transparent 
and avascular cornea and the sclera, covered by the richly 
vascularized conjunctiva. It represents the transition area 
between the corneal epithelium and the epithelium of the bulbar 
conjunctiva. Basically, there are three ways in which the limbus 
can be described: anatomical, histological and surgical [18]. 
The limbal epithelium is a transitional epithelium between two 
biologically different areas: the conjunctival area, vascularized 
and rich in lymphoid elements, and the corneal, avascular and 
richly innervated area [19]. At this level, the epithelium and 
conjunctival stroma are organized into papillary formations, 
similar to dermal papillae, radially oriented and called ”Vogt 
palisades” (0.5 mm x 2-4 mm). Fine blood vessels, nerves, and 
lymphatic vessels pass through the palisades, inside which are 
the corneal stem cells [20].
The regeneration of the corneal epithelium depends on these 
stem cells [14]. The term was introduced by Till and McCulloch 
[15], and defines cells with self-regenerative and differentiation 
potential in all cell types [16]. The limbal stem cell theory has 
crucially changed the therapeutic approach to ocular surface 
pathologies in humans, allowing the destruction of the ocular 
surface of various etiologies (inflammation, burns, trauma) to 
be treated by auto- or allografts of limbal stem cells, all on AM 
support [17]. Limbal stem cells prevent the invasion of the corneal 
epithelium by the conjunctival one, ensuring the transparency 
of the cornea. The corneal epithelium contains keratin 3 
and 12 (K3/K12) and the cells of the conjunctival epithelium 
contain keratin 7 and keratin 19 (K7/K19) [17]. Specific cellular 
markers can assess the degree of cell differentiation, and these 
markers can be used to demonstrate limbal stem cell failure 
syndrome. Detection of MUC5AC transcription in corneal 
epithelial cells, by polymerase chain reaction, is a method of 
molecular diagnosis of limbal stem cell failure. In the case of 
destruction of all limbal stem cells, the conjunctival epithelium 
would replace the corneal one, the cornea becoming opaque. 
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This demonstrates that the limbus is essentially involved in 
regulating the differentiation of the corneal epithelium [19]. 
Regulatory dysfunction of cell differentiation in limbal stem cell 
insufficiency leads, either to corneal epithelial metaplasia (in 
which case the corneal epithelium can "conjunctivalize"), or to 
its dysplasia with carcinogenesis [21].
Conjunctiva and cornea respond very differently to the 
aggressions to which they are exposed (mechanical, microbial, 
toxic): the conjunctiva is immunologically hyperactive, whereas 
the cornea benefits from the so-called immune privilege and 
inhibition of inflammatory reactions, in order to preserve its 
transparency. Immunological reactions, at the ocular surface 
level, are performed through a complex network of inflammatory 
cells, cytokines and chemokines. There is a dual unitary system: 
innate and acquired, which works complementarily and/or 
intricately [22].
LSCD is a complex ophthalmic disorder that accompanies 
a number of congenital or acquired pathological conditions, 
resulting in the total or partial dysfunction of these cells. The 
clinical resonance of LSCD derives from this dysfunction, with 
the most severe effects on the integrity of the cornea and the 
entire ocular surface [14, 16]. The etiology of LSCD is varied; 
from chemical, thermal and mechanical aggressions of the 
limbus (burns, multiple surgeries, antimitotic agents, dry 
eye syndrome, etc.), to infections (recurrent ulcer), chronic 
inflammation, neoplasms and destruction of the corneal matrix 
(neurotrophic keratitis) [23]. Chronic corneal ulcer and corneal 
neovascularization are the main complications of LSCD.
AMT acts in LSCD through several mechanisms:
a) prolongs the lifespan and maintains the clonogenicity of 
the progenitor epithelial cells;
b) favors the differentiation of epithelial cells, avoiding the 
differentiation into goblet cells;
c) favors the differentiation of goblet cells in the presence of 
conjunctival fibroblasts;
d) inhibits inflammatory cells with antiprotease activity;
e) suppresses the molecular signaling system of TGF-beta 
and differentiation of normal fibroblasts [24].
The AM is a tissue, unique in its biochemistry. In terms of 
lack of immunogenicity – it is the ideal transplant; in terms of 
the richness of growth factors and cytokines – it is a tissue that 
facilitates healing; in terms of harvesting and transplantation 
technique – it is affordable. All these qualities argue for the use 
of the AM in severe pathology of the ocular surface.
C. Sampling, processing and preserving the amniotic 
membrane
The potential donor is assessed before birth and after 
expressing full consent. AM should be obtained aseptically, after 
cesarean section, in a full-term pregnancy. It is excluded to take 
the AM after vaginal birth, because it can be contaminated with 
the saprophytic flora of the birthways. Diseases of the urogenital 
tract, other diseases of the donor or fetus, that may present a 
risk to the recipient, include: significant local bacterial, viral, 
parasitic or fungal infections of the genital tract, especially 
chorioamnionitis; (known) malformations of the newborn; 
premature rupture of membranes; endometritis; meconium 
ileus; tuberculosis, syphilis, HIV/AIDS; viral hepatitis B, C, D 
[25].
Taken samples are processed to facilitate longer storage 
periods until transplantation. Fetal membranes should be 
rinsed several times, the amnion and the chorion should be 
mechanically separated, and blood residues should be removed. 
The amnion must be placed separately on a suitable support 
membrane (e.g. nitrocellulose), where it must be divided into 
smaller pieces (50x30 mm) [26].
There are several methods for preparing and preserving AM.
Cryopreservation
The AM can be cryopreserved in a cryoprotective medium 
(10% dimethyl sulfoxide), using a suitable container (bags or 
cryotubes) and transferred to liquid nitrogen tanks (vapor phase, 
below -130°C). However, when AM is stored in a sterile glycerol 
medium (and nutrient medium), the storage temperature is 
usually below -75°C [27].
Thermally dried AM
The tissue is dried overnight in an oven at 40°C ± 2°C, and 
then sterilized with radiation. The membrane loses many of its 
biological properties due to the high temperature, so the AM 
kept this way is usually employed as a biological dressing for the 
management of burns.
Preservation of the AM with dry air
After the AM is separated and washed under sterile 
conditions, it is dried overnight with dry air in a laminar flow 
hood. It can then be packaged and sterilized with radiation. 
Although high temperatures are not applied using this method, 
some properties of the amnion are lost or altered, due to 
dehydration. AM prepared this way can be used for dressings. 
Air-dried AM must be transported at room temperature [28].
Lyophilized AM
AM can be cut into pieces and quickly frozen at -50°C to 
-80°C. It is then dried under vacuum, using a freeze-drying 
device. The water from the tissue is extracted by sublimation, 
until a final water content of 5-10% is reached. The tissue can 
then be packaged and sterilized by irradiation. This type of 
preparation induces minimal changes in the properties of the 
amniotic membrane, and the product can be stored at room 
temperature. Freeze-dried AM should be transported at room 
temperature. AM preserved by this method is mainly used for 
wound management [29].
Preservation in cold glycerol
Glycerol has long been used as a cryoprotective agent. Due 
to its high osmotic potential, it can extract interstitial water 
from AM. 80% glycerol is normally used to store the AM. Under 
such conditions, AM can be stored at 2-8°C for a long period, 
although it loses some of its biological properties. AM kept this 
way is used as a biological dressing for burns.
AM soaked in antibiotics
After separation, the AM is placed overnight in a solution 
consisting of various types of broad-spectrum antibiotics, 
an antifungal agent and a nutrient medium. It is then frozen 
at -80°C. The resulting AM is convenient for the treatment 
of infected wounds in combustion, by ensuring an adequate 
concentration of antibiotics on the wound surface [30].
D. Principles and surgical methods of amniotic membrane 
implantation
Determination of AM orientation on the ocular surface
The indication for which the AM is used and the desired 
final effect, determine the orientation with which it is applied to 
the ocular surface. Histopathological analysis showed that, after 
the application of AM, repopulation of the ocular surface by the 
host epithelium (e.g. the host corneal or conjunctival epithelium) 
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occurs preferentially on the basement membrane side of the 
epithelium [31], although, Seitz et al. [32] demonstrated that 
corneal epithelial cells also have the ability to grow on the 
stromal side of the membrane. When the membrane is used 
to secure the conjunctival or corneal cells with a substrate on 
which they could grow, AM is applied with the epithelial/basal 
face up. On the other hand, the stromal matrix of AM has the 
ability to capture inflammatory cells and induce their apoptosis, 
thus regulating the inflammatory response [33]. Thereby, in the 
presence of acute inflammation, the membrane can be used to 
protect the ocular surface from the harmful effects of cells and 
proinflammatory mediators. In this case AM is applied with the 
epithelial face down, so that the stromal face is oriented towards 
the eyelids.
The AM, provided on the nitrocellulose filter paper, is 
usually oriented with the epithelial side up, with the stromal 
face in direct contact with the paper. The stromal surface can 
be identified by the presence of vitreous-like strands that can be 
lifted with a sponge or fine forceps. Depending on the indication 
for which it is used, there are three surgical techniques by which 
AM can be applied to the ocular surface.
Inlay technique (“graft”)
In this technique, AM is intended to act as a substrate for 
epithelial cell growth. The AM is placed with the epithelial/
basement membrane facing up and cut to fit the size of the 
underlying epithelial or stromal defect. It is usually secured 
to the cornea with a 10-0 nylon suture or to the episclera and 
conjunctiva, using a 9-0 or 10-0 vicryl thread. It is preferable 
to keep the epithelium up in this technique, as the amniotic 
basement membrane acts as an excellent substrate for the 
growth of progenitor epithelial cells, by prolonging their 
lifespan, maintaining clonogenicity and preventing apoptosis 
[34]. Approximately 1-2 mm of the surrounding epithelium of 
the host cornea is debrided. This ensures that the regenerated 
epithelium grows over the basement membrane of the AM and, 
therefore, the amniotic stroma becomes embedded in the host 
tissue (graft). Depending on the depth of the underlying defect, 
this technique can use a single layer of AM (single-layer graft) 
or several (multi-layer graft). In the second case, several layers 
of unsutured AM are placed in the ulcer crater, over which a last 
layer of AM sutured to the edges of the ulcer is placed, after a 
prior deepithelization and debridement of the area around the 
corneal defect. The epithelium is to grow over the top layer of 
this multilayer graft. Layering can be done either by cutting the 
AM into several pieces and placing them on top of each other, 
or using a larger piece of folded AM.
Overlay technique (“patch”)
In this case, a fragment of AM, larger than the underlying 
defect, is sutured to the ocular surface so that the host epithelium 
is completely covered by the membrane. The AM is secured to 
the perilymbal conjunctiva using 9-0 vicryl or 10-0 nylon suture. 
The membrane can be placed with both the epithelial side and 
the stromal side up, as the host epithelium is to regenerate under 
the membrane, which, in this case, acts as a therapeutic contact 
lens or a biological bandage, designed to protect the new and 
fragile epithelium from the forces of friction generated by eyelid 
movements. In this situation, the AM either decomposes, or is 
removed after a certain period.
Combined technique (“sandwich”)
In this technique, two or more layers of AM are used - the 
inner layer or layers serving as a graft and the larger outer layer 
serving as a patch. Also, known as the "sandwich" technique, 
this method involves combining single-layer or multi-layer graft 
techniques ("inlay") with biological patching ("overlay"). In this 
case, the epithelium is expected to grow under the bandage, but 
over the graft.
The availability of fibrin glue for ophthalmic use has, in 
many cases, replaced the application of sutures, and the AM can 
be adhered to the ocular surface using recombinant fibrin glue. 
This reduces the time of intervention, but also increases patient 
comfort [36, 45].
E. Limbal stem cell deficiency - surgical treatment using 
amniotic membrane 
1. Isolated AMT
AMT can be used in the treatment of chemical burns and 
thermal injuries, due to its properties of epithelium healing [35]. 
It also seems to be beneficial in managing the Stevens-Johnson 
Syndrome, thanks to its anti-inflammation properties [36]. Here, 
the AM is acting as a temporary patch, protecting the ocular 
surface, promoting epithelial healing and preventing cicatricial 
sequelae. That being said, controlled clinical trials failed to show 
any definitive long-term benefits of AMT alone, in comparison 
to medical therapy, when it comes to visual outcome, ocular 
surface integrity and corneal vascularization [37]. AMT has 
also been used for treating partial LSCD [38]. In this case, as 
histological findings show, the effect of AM is believed to reside 
in its biological properties rather than mechanical ones [39].
Surgical technique
After fibrovascular pannus was surgically debrided and 
the inflamed tissue was removed, AM was taken out from the 
container with a suitable storage environment and placed over 
the freshly denuded cornea and limbus. In most studies, AM 
was placed with the epithelium facing up [40, 41, 42]. AM was 
secured either to the cornea, with 10-0 nylon sutures [40, 43], 
or to the perilimbal conjunctiva using 9-0 Vicryl sutures [24, 
Table 1
Outcomes of AMT alone, in patients with LSCD
Year of publication Author No of eyes Mean age Re-epithelialization 
(weeks)
Stable cornea (%) VA improvement 
(%)
Follow-up 
(months)
2015 Chugh JP [41] 30 48.9±16.3 2 - 55 6
2013 Konomi K [38] 16 57.4±16.4 1.5 31.2 31 52.3±26.3
2008 Kheirkhah A [48] 11 32.4±18.4 2.5 72.7 - 14.2±7.7
2005 Lopez-Garcia JS [47] 14 37 2 - 60 24
2005 Ivekovic R [42] 5 31.6±12.3 3 60 80 18±4.3
2003 Gomes JA [46] 4 34.5±26.3 3 - - 17.5±5.1
2001 Anderson DF [40] 17 42.3±4.6 2.5 58.8 29 25.8±2.5
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44]. In the latest studies, there were reports that fibrin glue can 
prevent suture-related complications [36, 45].
Results
We selected 7 studies [38, 40-42, 46-48] that reported results 
of isolated AMT in the treatment of partial LSCD (Table 1). 
Complete corneal and conjunctival re-epithelialization usually 
occurred in 1.5-3 weeks [38, 40, 46]. Stable epithelial surface 
was maintained during a period of 12-25 months after surgery 
[40, 42, 47]. Visual acuity (VA) has improved in 29-80% of 
operated eyes [38, 40-42, 46, 48]. Nonetheless, the success rate 
of AMT alone, in patients with LSCD, was only 31% at over a 50 
months follow-up period [38].
2. Transplantation of limbal tissues combined with AM
There are three methods of direct limbal tissues transplan-
tation: conjunctival limbal autograft transplantation (CLAU), 
conjunctival limbal allograft transplantation (CLAL) and 
keratolimbal allograft transplantation (KLAL). Because there 
is no consistent data on KLAL, we didn’t include these studies 
into the analysis. Instead, we focused mainly on the techniques, 
indications and effectiveness of CLAU and CLAL combined 
with AMT.
Surgical technique
Inlay technique: In this case, AM was placed on the ocular 
surface and sutured, then the limbal graft was secured to the 
recipient limbal area [24, 28]. This way, AM is believed to 
alleviate inflammation and scarring after surgery. Additionally, 
the combination of AMT may improve the regeneration of LSCs 
[49] and decrease the risk of induced LSCD in the donor’s eye.
Overlay technique: After the application of limbal tissues, 
AM was placed as a temporary patch over the grafts, covering 
the entire ocular surface [50]. In some cases, AM was placed 
first under and then over the transplanted limbal grafts – the so 
called “sandwich” technique [49]. Here, the AM plays the role 
of a contact lens, providing mechanical protection and relieving 
postoperative pain and discomfort.
Results
A total of 15 studies [42, 46, 51-63] were selected for the 
analysis of the outcome of CLAU or CLAL (Table 2). The follow-
up period in these studies was at least 12 months. One study 
[42] compared the re-epithelialization times in three distinct 
groups: after AMT (24 days), CLAU (14 days), and CLAU plus 
AMT (15 days). No notable difference was reported between 
CLAU and CLAU combined with AMT, but there was a greater 
re-epithelization time when AMT was used alone. Another 
study [51] showed that, even though the graft success rate was 
somewhat similar between the tested groups regardless of the 
use of AMT, the re-epithelialization was considerably slower in 
the group with AMT. However, the lack of sufficient comparative 
studies and the difference between study designs and population 
structure means that there is insufficient data to demonstrate the 
effectiveness of combining AMT with CLAU or CLAL [46, 52-
55, 62]. Nonetheless, AMT is being actively used as a common 
procedure in direct limbal tissue transplantation for its healing 
properties and to increase graft survival rate [56, 57].
Table 2
Outcomes of AMT+CLAU/CLAL in patients with LSCD
Year of publication Author No of eyes Mean age Re-epithelialization 
(weeks)
Stable cornea (%) VA improvement 
(%)
Follow-up 
(months)
2017 Arora R [55] 10 18±8 2.5 90 33 6
2015 Moreira PB [58] 28 40.3 4 - - 24.8
2014 Barreiro TP [51] 15 36.3 2 73.3 66 19.7±5.6
2012 Baradaran-Rafii [56] 34 27.3±9.4 3.5 - 58 17.2±6.3
2012 Eberwein P [59] 20 44 1.5 - - 22.4
2011 Han ES [60] 24 39.4±17.4 4 66.6 62 47.3±22
2010 Miri A [57] 27 - 2 - 48 38±35.9
2008 Scocco C [54] 39 33.6±18.9 1.5 69.2 - 48.7±30.6
2008 Shi W [61] 39 - 2 - 38 32
2006 Maruyama-Hosoi F [62] 85 52.5±19.5 2 69.4 - 46.6
2005 Santos MS [53] 33 35±16 3.5 - 51 33±12
2005 Lopez-Garcia JS [47] 14 47 2 78.5 60 24
2005 Ivekovic R [42] 4 27.8±7.8 3 100 - 12.8±1.7
2004 Shimazaki J [63] 21 43.2±19.1 2.5 - 80 15
2003 Gomes JA [46] 16 42.3±11.2 3 87.5 62 18.3±6.1
3. Transplantation of ex vivo expanded LSC on AM
This method of treatment is used in cases of bilateral, 
complete limbus injury, or when there is not enough healthy 
limbal tissue in the contralateral eye to collect sufficient LSCs. 
There are two main surgical procedures: cultivated limbal 
epithelial transplantation (CLET) and cultivated oral mucosal 
epithelial transplantation (COMET) [64]. The source of cells 
can be either autologous, or allogenic. The main advantage of 
these techniques is the small size of donor tissue (<1 mm2) [65], 
while, also, presenting a low risk of damaging the donor eye. 
AM here serves as a carrier for cultured cells. De-epithelialized 
AM is preferred over the intact AM, as it better facilitates the 
migration of LSCs. It has also been reported that AM provides 
a beneficial stromal microenvironment for LSCs expansion 
and preservation. Furthermore, it is believed that AM protects 
cultured LSCs from apoptosis [66].
Cultivation on AM
One method of cultivation is chopping the tissue into small 
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fragments and subsequently placing it on the epithelium side 
of the AM [67]. Another method consists in obtaining single 
cell suspension by incubating the tissue with trypsin and then 
seeding the cells on AM [64, 68].
The minimal size of live limbal tissue, required to obtain 
enough cells for expansion and transplantation, is 0.3 mm2 
(0.5 mm2 for cadaveric limbal tissue) [69]. For oral mucosal 
epithelium, a specimen of 3 mm2 is required [70].
Surgical technique
The fibrovascular pannus is surgically debrided and the 
perilimbal scarring tissue is removed at least 2 mm behind the 
limbus. The cultivated epithelial cells, together with the AM 
substrate, are then placed on the cornea, with the epithelial side 
facing up, and secured with sutures to the ocular surface.
Results
A total of 23 studies [71-93] were selected for the analysis 
of the outcome of CLET and COMET combined with AM 
substrate (Table 3). The rejection rate of CLET was relatively 
low, even when allogenic tissue was used, thanks to the small 
size of transplanted tissue [94], and the rate of success was 
stable even after one year [68, 71]. Similarly, the successful rate 
of COMET was stable two years after surgery [72]. The result of 
immunostaining and PCR showed that although oral mucosal 
epithelial cells expanded on AM became phenotypically similar 
to limbal and corneal epithelium, they did not undergo a 
veracious differentiation [73].
Table 3
Outcomes of CLET/COMET on AM substrate in patients with LSCD
Year of publication Author No of eyes Mean age Re-epithelialization 
(weeks)
Stable cornea (%) VA improvement 
(%)
Follow-up 
(months)
2017 Parihar JK [74] 25 46±6 3 88 40 12
2017 Cheng J [75] 80 42.4±13.7 2.5 - - 26.4±13.6
2016 Scholz SL [76] 61 48.9±17.5 4 - - 50.8±32.7
2016 Prabhasawat P [73] 20 48.2±15.5 2 75 38 31.9±12.1
2015 Ramirez BE [77] 20 51.6±14.2 1.5 - - 36
2015 Ganger A [71] 62 14.7±10 3 82.2 42 21.4±17.8
2015 Dobrowolski D [90] 17 31.1±11.5 3 - 44 16±2.2
2014 Zakaria N [78] 18 40.7±19.4 4 72.2 - 23.7±13.3
2014 Vazirani J [79] 70 24±12.5 3 72.8 38 17.5±7
2013 Subramaniam SV [80] 40 16.8±9.3 3 - 51 33.4±29.2
2013 Sejpal K [81] 107 7.5±3.72 2.5 68.2 41.2±26
2013 Qi X [82] 42 38±14.7 3.5 73.8 39 17.8±3.8
2012 Prabhasawat P [83] 19 44.7±15.2 4 - - 26.1±13.5
2012 Basu S [84] 50 20.7±11.4 3 74 55 27.6±16.8
2012 Basu S [85] 28 27.9±17.4 2 - 38 58±33.6
2012 Hirayama M [91] 16 58.4±17.7 2.5 75 - 35±17.6
2011 Sharma S [86] 50 14.5±10 4 24 - 13.8±2.9
2011 Sangwan VS [87] 200 24.1±9.9 3 64.5 59 36±19.2
2011 Satake Y [92] 40 58.5 3.5 - 75 25.5
2011 Nakamura T [72] 19 54±21 1.5 63.1 - 55±17
2010 Pauklin M [88] 44 47.4±20.1 4 - 80 28.5±14.9
2010 Meller D [89] 30 47.4±20.1 2.5 73.3 62 28.9±15.5
2006 Inatomi T [93] 15 48.4±22.3 3 - - 20±11
4. Transplantation of in vivo expanded LSC on AM
This new surgical technique, called Simple Limbal Epithelial 
Transplantation (SLET), is usually employed in the management 
of unilateral LSCD. It consists in the in vivo expansion of 
limbal tissue pieces on AM. Because it is relatively cheap, easy 
to perform and requires very low amounts of donor tissue, it 
combines the advantages of both CLAU and CLET techniques.
Surgical technique
AM is secured on the ocular surface with the epithelial side 
up and the donor limbal tissue is then placed on the AM [55, 95]. 
There are, also, modified versions of SLET. Instead of placing the 
limbal explants on the AM, they can also be placed directly on 
the cornea, using the AM to cover both the grafts and the entire 
ocular surface [96]. Another modification, called “sandwich 
technique”, consists in placing the donor tissue between two 
layers of AM [97].
Results
A total of 4 [95, 98-100] studies were selected (Table 4). 
Although the follow-up period was relatively short (up to 18 
months), SLET showed excellent results in the treatment of 
LSCD. Re-epithelialization was achieved in 3-4 weeks after 
surgery, while stable avascular cornea was reported in 80% cases 
at 12 months and in 76% cases at 18 months [95, 99].
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Conclusions
1. The ocular surface is one of the targets of biological and 
bio-artificial regeneration technologies. The AM, due to its 
composition and unique properties, explains the special interest 
of researchers especially through its implications in regenerative 
medicine. 
2. Studies on laboratory animals highlight the beneficial 
properties of the AM; anti-inflammatory, antimicrobial, 
antifibrotic and antiadhesive, analgesic and antiangiogenic. 
In addition, the AM is a promoter of cell differentiation and 
adhesion, with a low level of antigenicity through epithelial cells 
in the amniotic epithelium that have stem-like qualities.
Table 4
Outcomes of SLET in patients with LSCD
Year of publication Author No of eyes Mean age Re-epithelialization 
(weeks)
Stable cornea (%) VA improvement 
(%)
Follow-up 
(months)
2017 Iyer G [98] 18 - 4 100 - 10.3±6.7
2017 Arora R [55] 10 15.2±10.8 3 100 80 6
2016 Vazirani J [99] 68 22 3 80 61 12
2016 Basu S [95] 125 - 4 76 58 18
3. Used in tissue engineering, the AM is an exoskeleton with 
a particular pattern of extracellular matrix components, having 
the capacity to modulate wound healing by promoting tissue 
reconstruction. For this reason, the AM has been employed as a 
substrate in numerous surgical techniques, particularly in those 
used for treating partial or total LSCD.
4. The approach in treating LSCD depends on the extent 
of the disease. Isolated AMT appears to have modest results 
in the long term. Although studies have consistently reported 
favorable outcomes of different LSC transplantation techniques 
combined with AMT, currently, it is unclear what is the role of 
AM specifically and to what extent it impacts the final result.
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